JAMP Pharma Group Launches Generic Enzalutamide for Prostate Cancer Treatment in Canada
核心洞察
JAMP Pharma Group (搜索) has launched PrJAMP Enzalutamide (搜索), a generic alternative to PrXtandi (搜索) for prostate cancer treatment in Canada, marking the company's 12th oncology product.
The oral antiandrogen medication is indicated for multiple stages of prostate cancer including non-metastatic and metastatic castration-sensitive and castration-resistant forms.
The launch provides Canadian patients with a lower-cost therapeutic option while expanding access to critical prostate cancer therapies through JAMP's specialized patient support program.
JAMP Pharma Group (搜索) announced the launch of PrJAMP Enzalutamide (搜索) in Canada on March 16, 2026, providing a second generic alternative for prostate cancer treatment. The oral antiandrogen medication serves as a generic alternative to the reference product PrXtandi (搜索), marketed in Canada by Astellas Pharma Canada Inc (搜索).
The launch represents a significant expansion of JAMP's oncology portfolio, bringing the company's specialty products to 12 medications. "The launch of PrJAMP Enzalutamide (搜索) marks an important step in our mission to improve accessibility to important oncology care in Canada," said Louis Pilon, President and CEO of JAMP Pharma Group (搜索). "By adding this 12th product to our oncology portfolio, we are not only offering a lower-cost therapeutic option for prostate cancer patients but also reaffirming our role as a partner of choice for healthcare professionals."
Clinical Applications and Indications
PrJAMP Enzalutamide (搜索) is indicated for multiple stages of prostate cancer treatment, including:
- Non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)
- Metastatic castration-sensitive prostate cancer (mCSPC)
- Non-metastatic castration-resistant prostate cancer (nmCRPC)
- Metastatic castration-resistant prostate cancer (mCRPC) in the context of medical or surgical castration, specifically in certain patients prior to chemotherapy or following docetaxel treatment
The medication is available in 40 mg oral capsules, packaged in boxes of 120 capsules containing 30 blister packs of 4 capsules each.
Enhanced Patient Support Services
JAMP has integrated all its oncology products under the JAMP Care program, which provides comprehensive patient support services. "All our oncology products are now grouped under a single patient support program (PSP), JAMP Care, which offers a unified and highly specialized structure," explained Amélie Faubert, Senior Vice President, Institutional Affairs & Specialty Products.
The program offers patients a comprehensive range of services including nutritional services, kinesiology, guidance throughout the oncology journey, sex therapy, and social worker support. This integrated approach ensures seamless transitions and close collaboration with healthcare teams across Canada.
Market Position and Manufacturing Capabilities
JAMP Pharma Group (搜索) maintains the largest selection of generic medications in Canada, with nearly 350 molecules actively marketed. The company was among the first to obtain a Notice of Compliance for enzalutamide in the Canadian market, demonstrating its regulatory expertise in complex generic drug development.
Since 2024, JAMP has operated its own manufacturing plant in Lévis, supporting continuous access to quality medications for Canadians. The facility enhances the company's service capabilities for community pharmacies and hospitals, enabling optimal service delivery and continuity of care for patients.
The launch of PrJAMP Enzalutamide (搜索) reinforces JAMP's commitment to providing lower-cost therapeutic options while maintaining quality standards, potentially generating substantial savings for Canada's public and private healthcare systems.